FDA deal allows Amarin to promote drug for off-label use

New York

IN a deal that could change the way some companies market their drugs, the Food and Drug Administration has agreed to allow a pharmaceutical company to promote a drug for a use that the agency has not approved, the company said on Tuesday.

The agreement settles a legal case between the agency and the company, Amarin, a small drugmaker that sued the FDA last year for the right to promote its only product, Vascepa, to a broader range…